Suppr超能文献

Xen-45 凝胶支架在葡萄膜炎继发性青光眼的紧急处理中的应用

Urgent Management of Secondary Glaucoma in Uveitis Using the Xen-45 Gel Stent.

机构信息

Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust.

Medical Academic Health Science Center, University of Manchester, Manchester, UK.

出版信息

J Glaucoma. 2019 Dec;28(12):1061-1066. doi: 10.1097/IJG.0000000000001389.

Abstract

PRECIS

The Xen-45 implant is an effective and safe treatment option for patients with medically uncontrolled glaucoma in the setting of uveitis, including those where urgent surgical intervention is required.

PURPOSE

The purpose of this study was to report the efficacy and safety of the Xen-45 gel stent in eyes with glaucoma secondary to uveitis.

METHODS

Retrospective observational case series of 37 eyes, with medically uncontrolled glaucoma in uveitis using Xen-45 implantation. All patients had at least 12 months follow-up. Primary outcome measures included visual acuity, intraocular pressure (IOP), degree of inflammation and ocular hypotensive medications. In addition, the time taken from the decision to surgery was recorded. Data were collected preoperatively and 1 day, 1 week, 1, 3, 6, and 12 months postoperatively. Postoperative complications included hypotony and decompressive retinopathy. The requirement for further glaucoma surgery, including bleb needling, and failure were documented.

RESULTS

The mean follow-up time was 16.7 months (range: 12 to 32 mo). Preoperatively all patients were on >3 ocular hypotensive medications and 75.7% were on oral acetazolamide. Systemic immunosuppression was used in 62.2% and all were on topical steroids. Mean preoperative IOP was 36.1 mm Hg (±SD 9.6) on an average 3.69 (±SD 0.47) drops. The median time from decision to operate to surgery was 5.5 days (range: 1 to 120 d). Mean postoperative IOP was 12.6 mm Hg (±SD 4.1) with an average 0.62 (±SD 1.1) drops at 1 year representing a 65% drop in IOP and 83% reduction in IOP-lowering medication. Bleb needling with 5-fluorouracil was performed on 5 eyes (13.5%). Symptomatic hypotony occurred in 7 eyes requiring further interventions. No decompressive retinopathy was found at last follow-up. Five eyes (13.5%) failed, needing drainage tube surgery or trabeculectomy.

CONCLUSIONS

The Xen-45 implant is an effective treatment for hypertensive crises in glaucoma in uveitis, offering dramatic IOP lowering without significant uveitis flare-up. In this group of patients with uveitis, needling rates are lower than reported in primary open-angle glaucoma. However, complications including hypotony can still occur.

摘要

摘要

Xen-45 植入物是一种针对葡萄膜炎相关药物难治性青光眼的有效和安全的治疗选择,包括那些需要紧急手术干预的患者。

目的

本研究旨在报告 Xen-45 凝胶支架在治疗葡萄膜炎继发青光眼方面的疗效和安全性。

方法

回顾性观察性病例系列研究,纳入了 37 只患有葡萄膜炎相关药物难治性青光眼的眼睛,使用 Xen-45 植入物治疗。所有患者的随访时间均至少为 12 个月。主要观察指标包括视力、眼内压(IOP)、炎症程度和降眼压药物。此外,还记录了从决定手术到手术的时间。数据在术前和术后 1 天、1 周、1、3、6 和 12 个月采集。术后并发症包括低眼压和减压性视网膜病变。记录了进一步的青光眼手术(包括小梁切开术)的需求和失败情况。

结果

平均随访时间为 16.7 个月(范围:12 至 32 个月)。术前所有患者均使用≥3 种降眼压药物,75.7%的患者使用口服乙酰唑胺。62.2%的患者使用全身免疫抑制剂,所有患者均使用局部皮质类固醇。术前平均 IOP 为 36.1mmHg(±9.6mmHg),平均使用 3.69(±0.47)滴降眼压药物。从决定手术到手术的中位时间为 5.5 天(范围:1 至 120 天)。术后 1 年平均 IOP 为 12.6mmHg(±4.1mmHg),平均使用 0.62(±1.1)滴降眼压药物,IOP 降低 65%,眼压降低药物减少 83%。5 只眼睛(13.5%)需要行小梁切开术联合 5-氟尿嘧啶眼内注射。7 只眼睛(18.9%)出现症状性低眼压,需要进一步干预。末次随访时未发现减压性视网膜病变。5 只眼睛(13.5%)失败,需要引流管手术或小梁切除术。

结论

Xen-45 植入物是治疗葡萄膜炎相关青光眼高血压危象的有效方法,可显著降低 IOP,且不会引起明显的葡萄膜炎发作。在这组葡萄膜炎患者中,小梁切开术的发生率低于原发性开角型青光眼的报道。然而,仍可能发生低眼压等并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验